ALLO Open Interest
Allogene Therapeutics Inc (ALLO) had 17.02K open option contracts as of Nov 4, 2026: 15.38K calls and 1.64K puts. Open interest rose 12.7% over the past four weeks, and is ALLO's highest level in 4 weeks. The put/call open interest ratio is 0.11, so calls outnumber puts.
Open Interest by Strike
Showing results for ALLO, 2026-11-20(m), calls & puts
Open Interest Stats
Showing results for ALLO, 2026-11-20(m), calls & puts
| Call Open Interest Total | |
|---|---|
| Put Open Interest Total | |
| Open Interest Total | |
| Put-Call Open Interest Ratio |
Highest Open Interest Options
Showing results for ALLO, 2026-11-20(m), calls & puts
Open Interest Total by Expiry
Showing results for ALLO, 2026-11-20(m), calls & puts. View all expiries
Open Interest History
Showing daily totals for ALLO, all expirations, calls & puts. View full history
ALLO Open Interest FAQ
What is open interest?
Open interest is the number of option contracts that are open and not yet closed, exercised, or expired. The Options Clearing Corporation calculates it once a day from the previous day's trades, and it is published before the market opens.
How much open interest does ALLO have?
Allogene Therapeutics had 17.02K open option contracts as of Nov 4, 2026. Over the past 30 days, open interest averaged 15.64K contracts.
Is ALLO open interest rising or falling?
Open interest rose 12.7% over the past four weeks, and is ALLO's highest level in 4 weeks. It was 15.1K contracts on Oct 7, 2026. See the ALLO open interest history for a longer view.
What is the ALLO put/call open interest ratio?
The Allogene Therapeutics put/call open interest ratio was 0.11 as of Nov 4, 2026. Four weeks earlier it was 0.09.
What is Allogene Therapeutics Inc?
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.